CE Mark brings the increased functionality of the AtriClip PRO2
device to the European market for use in managing the left atrial
appendage; product was launched in the U.S. in April 2016
MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016--
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA)
Exclusion System, which offers increased functionality to occlude the
LAA during minimally-invasive surgical (MIS) procedures. The device was
previously launched in April 2016 with FDA 510(k) Clearance in the
“We are excited to bring the AtriClip PRO2 device to the European
market,” said Michael Carrel, President and CEO of AtriCure. “The US
launch has been well received by our customers and we’re looking forward
to the continued growth of the AtriClip franchise.”
The addition of the AtriClip PRO2 device has expanded the left atrial
appendage product offerings and now provides an ambidextrous locking and
trigger-style clip closing mechanism, handle-based active articulation
levers, and a hoopless end effector. These features have improved the
ease of use and time it takes to manage the left atrial appendage.
For more information about the AtriClip franchise or left atrial
appendage management visit our website at http://www.atricure.com/atrial-occlusion.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip® left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that is indicated for
the occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. AtriCure recently acquired nContact, a leader in minimally
invasive technology for epicardial ablation. nContact’s mission is to
transform the underserved arrhythmia population through a
multidisciplinary epicardial-endocardial ablation approach. Afib affects
more than 33 million people worldwide. For more information visit
AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005225/en/
Source: AtriCure, Inc.
Corporate Marketing and Communications
Senior Vice President and Chief